Sergio Giralt

Overview

Best Publications

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

  2920
  Citations

• Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

  Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley

  2376
  Citations

• Defining the intensity of conditioning regimens: working definitions.

  Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt

  1965
  Citations

• Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

  R H Collins;O Shpilberg;W R Drobyski;D L Porter

  1550
  Citations

• Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

  Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  1491
  Citations

• Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

  I F Khouri;M Keating;M Körbling;D Przepiorka

  1419
  Citations

• Lenalidomide after stem-cell transplantation for multiple myeloma

  Philip L. McCarthy;Kouros Owzar;Craig C. Hofmeister;David D. Hurd

  1323
  Citations

• The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

  Ying Taur;Ying Taur;Robert R Jenq;Robert R Jenq;Miguel Angel Perales;Miguel Angel Perales;Eric R. Littmann

  927
  Citations

• Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

  Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  909
  Citations

• Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

  Sergio Giralt;Karen Ballen;Douglas Rizzo;Andreas Bacigalupo

  864
  Citations

• Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease

  Robert R. Jenq;Robert R. Jenq;Ying Taur;Ying Taur;Sean M. Devlin;Doris M. Ponce;Doris M. Ponce

  796
  Citations

• Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

  Jonathan U Peled;Antonio L C Gomes;Sean M Devlin;Eric R Littmann

  698
  Citations

• Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts

  M Korbling;D Przepiorka;YO Huh;H Engel

  677
  Citations

• Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

  Jason A. Coppell;Paul G. Richardson;Robert Soiffer;Paul L. Martin

  652
  Citations

• Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse

  Stephanie J. Lee;John P. Klein;A. John Barrett;Olle Ringden

  637
  Citations

• Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

  Brian L. McClune;Daniel J. Weisdorf;Tanya L. Pedersen;Gisela Tunes da Silva

  619
  Citations

• Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

  Bart L. Scott;Marcelo C. Pasquini;Brent R. Logan;Juan Wu

  616
  Citations

• Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

  Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  563
  Citations

• Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

  Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva

  559
  Citations

• Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

  Marcos De Lima;Athanasios Anagnostopoulos;Mark Munsell;Munir Shahjahan

  528
  Citations